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BACKGROUND: Tumour-infiltrating lymphocytes (TILs) are predictors of disease-specific survival (DSS) in ovarian cancer. It is largely
unknown what factors contribute to lymphocyte recruitment. Our aim was to evaluate genes and pathways contributing to infiltration
of cytotoxic T lymphocytes (CTLs) in advanced-stage serous ovarian cancer.
METHODS: For this study global gene expression was compared between low TIL (n¼25) and high TIL tumours (n¼24). The
differences in gene expression were evaluated using parametric T-testing. Selectively enriched biological pathways were identified
with gene set enrichment analysis. Prognostic influence was validated in 157 late-stage serous ovarian cancer patients. Using
immunohistochemistry, association of selected genes from identified pathways with CTL was validated.
RESULTS: The presence of CTL was associated with 320 genes and 23 pathways (Po0.05). In addition, 54 genes and 8 pathways were
also associated with DSS in our validation cohort. Immunohistochemical evaluation showed strong correlations between MHC class I
and II membrane expression, parts of the antigen processing and presentation pathway, and CTL recruitment.
CONCLUSION: Gene expression profiling and pathway analyses are valuable tools to obtain more understanding of tumour
characteristics influencing lymphocyte recruitment in advanced-stage serous ovarian cancer. Identified genes and pathways need to be
further investigated for suitability as therapeutic targets.
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Epithelial ovarian cancer is the most common cause of death from
gynaecological malignancies (Parkin et al, 2005). The 5-year
survival rates for ovarian cancer patients do not exceed 40%. This
high mortality is best attributed to the absence of specific
symptoms combined with the lack of reliable screening methods,
which prevent diagnosis in the early stages of the disease in a
majority of patients. Treatment generally consists of cytoreductive
surgery followed by platinum- and taxane-containing chemother-
apy. Classic prognostic factors are stage of disease at diagnosis,
histological tumour type and grade, residual disease after primary
surgery, and response to chemotherapy (Crijns et al, 2006). An
increasing body of evidence suggests that next to these established
prognostic factors, the presence of tumour-infiltrating lympho-
cytes (TILs) also independently contributes to prognosis (Zhang
et al, 2003; Sato et al, 2005; Leffers et al, 2009a). Although the
presence of TILs is generally considered a reflection of antitumour
immunity, it is largely unknown why TILs are present in high
numbers in some tumours and largely absent in others. It has been
shown that endothelial factors and chemokines secreted by
the tumour may have an important role (Curiel et al, 2004;
Buckanovich et al, 2008). The existence of an antitumour immune
repertoire in a selection of patients forms the rationale for the
development of cancer immunotherapy. Although immunotherapy
strategies generally induce potent peripheral immune responses in
ovarian cancer patients, clinical responses have so far been
disappointing (Hung et al, 2008). The combination of targeted
agents that enhance lymphocyte recruitment to tumour sites with
these immunotherapy strategies might be a lucrative approach to
obtain clinical responses to immunotherapy. For instance, the
in vivo addition of BQ-788, an endothelin B receptor antagonist, to
previously immunogenic, but clinically ineffective, immunisation
strategies resulted in enhanced homing of lymphocytes to tumours
as well as improved clinical responses (Buckanovich et al, 2008).
To investigate what tumour factors contribute to the recruit-
ment of lymphocytes, we analysed which genes and pathways were
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sassociated with the presence of tumour-infiltrating CTLs in a
homogeneous group of 49 advanced-stage serous ovarian cancer
patients previously profiled at our institute as part of a larger study
(Crijns et al, 2009). The prognostic value of identified genes and
pathways was subsequently validated on all 157 previously profiled
late-stage serous ovarian cancer patients (Crijns et al, 2009).
Furthermore, immunohistochemical staining of tissue microarrays
was performed to validate findings.
PATIENTS AND METHODS
Patients
The presence of tumour-infiltrating T lymphocytes was previously
evaluated by our group in 306 ovarian cancer patients (Leffers
et al, 2009a). In short, we used a tissue microarray containing core
biopsies (0.283mm
2 each) of tumour tissue obtained from each
of 306 ovarian cancer patients at primary surgery. Sections
were stained with anti-CD8 (1:20; Dako Cytomation, Glostrup,
Denmark). The number of intraepithelial CD8
þ CTLs were
separately counted for each core and an average per core was
calculated when at least two cores were present for a single tumour
sample. Patients with 48 CD8
þ T lymphocytes per 0.283mm
2
were found to have a better prognosis. For this study, we selected
from this heterogeneous population only advanced-stage serous
ovarian cancer patients with low (p5 per 0.283mm
2 of tumour) or
high (X8 per 0.283mm
2 of tumour) CTL numbers who were also
included in the previously published microarray study (Crijns
et al, 2009). This large microarray study contained 157 advanced-
stage ovarian cancer patients for whom fresh frozen tumour tissue
was available. Only 63 of these patients were also represented on
our tissue microarray, of whom only 49 met the requirements
stipulated above.
Patients were treated at the University Medical Center
Groningen by a gynaecological oncologist and staged according
to FIGO classification (Cancer Committee of the International
Federation of Gynaecology and Obstetrics, 1986). Tumours
were graded and classified according to the WHO criteria by a
gynaecological pathologist (Scully, 1999). Adjuvant chemotherapy
generally consisted of different platinum-based treatment regi-
mens. Response to chemotherapy was evaluated according to the
WHO criteria (World Health Organization, 1979). After treatment,
patients were followed-up for at least 10 years with gradually
increasing intervals. Informed consent was obtained for the
collection and storage of tumour samples in a tissue bank for
future research. Information on clinicopathological characteristics
and follow-up of patients was obtained from a computerised
database in which information of all patients with epithelial
ovarian cancer treated at our institute is prospectively recorded.
For this study, relevant data were retrieved into a separate
anonymous database. In this separate database, patient identity
was protected by study-specific, unique patient codes. In case of
uncertainties with respect to clinicopathological and follow-up
data, the larger databases could only be checked through two data
managers who have daily responsibilities for the larger database,
thereby ascertaining the protection of patients’ identity. According
to Dutch law no approval from our IRB was needed.
Microarray analysis
As mentioned above, we selected 49 advanced-stage serous ovarian
cancer patients based on the relative absence or presence of CD8
þ
TILs, who were previously profiled as part of a larger study (Crijns
et al, 2009). In brief, after RNA extraction and amplification,
samples were hybridised to two-colour 70-mer oligonucleotide
microarrays (B35000 Operon v3.0 probes, Ebersberg, Germany).
All samples were hybridised at least twice and samples were loaded
using a random design to prevent systematic biases (Churchill,
2002; Kerr, 2003; Hsu et al, 2007). Arrays were scanned using the
Affymetrix GMS428 (Affymetrix, Santa Clara, CA, USA). Expres-
sion values were calculated using Bluefuse software (BlueGnome,
Cambridge, UK). Operon v3.0 probe identifiers were converted to
official gene symbols using probe annotations provided by The
Netherlands Cancer Institute (NKI, Amsterdam, The netherlands).
Only oligonucleotides specifically responding with a single hit on a
gene during a BLAST search were used. Expression values of
multiple probes targeting a single gene were averaged, resulting in a
total of 15909 distinct genes. Subsequently, expression data of the
multiple hybridisations per tumour sample were averaged. Micro-
array data of the previous, larger study from which our patients
were selected are available at http://www.ncbi.nlm.nih.gov/geo/
under number GSE13876.
Class comparison between low TIL and high TIL samples
The BRB Array Tools 3.6.0 software package, developed by the
Biometric Research Branch of the US National Cancer Institute,
was used for class comparison between low-TIL and high-TIL
samples. Differentially expressed genes were identified using
a paired T-test (threshold Po0.05).
Gene set enrichment analysis (GSEA)
As it is unclear whether large differences in the expression of
a single gene are biologically more relevant than more subtle,
although coordinated, differences in a set of genes belonging to a
single biological pathway, we performed gene set enrichment
analysis. Expression data of all 15909 genes were compared against
functional gene sets to determine whether any of these sets were
enriched in samples containing high or low numbers of CD8
þ
TILs. The comparison was performed using 340 gene sets reported
in two databases (174 sets from BIOCARTA: http://www.biocarta.
com; 166 sets from Kyoto Encyclopedia of Genes and Genomes
database (KEGG): http://www.genome.jp/kegg/). Statistical signifi-
cance of enrichment was determined using an empirical gene-
based permutation test using 1000 permutations. Gene sets with an
enrichment P-value of o0.05 are reported. We also calculated false
discovery rates (FDRs) for each functional gene set, which
represent the estimated probability that a given enrichment score
represents a false-positive finding. We only report gene sets with
an FDR of o0.25. With such an FDR, the results are likely to be
valid at least three out of four times, which is considered a suitable
cutoff for the generation of interesting hypotheses (Gu et al, 2007).
The GSEA was executed using the GSEA 2.0 software package
(Broad Institute of MIT and Harvard, Cambridge, MA, USA).
Leading-edge subset analysis
The leading-edge subset is defined as the subset of genes in a
functional gene set that appears in the ranked list of 15909 genes
at, or before, the point in which the running enrichment score
reaches its maximum deviation from zero. The genes within this
subset can be interpreted as the most important in the enrichment
of the functional gene set. Leading-edge subsets were defined for
all statistically enriched function gene sets (Po0.05). Sub-
sequently, overlap between leading-edge subsets from significantly
enriched functional gene sets identified in the different databases
was determined to discover genes belonging to more than one
leading-edge subset, that is, possible key genes.
Prognostic value of identified genes and pathways
Genes identified as differentially expressed between high and low
TIL-containing samples were correlated with disease-specific
survival (DSS) in a large cohort of 157 late-stage ovarian cancer
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spatients previously profiled at our institution (Crijns et al, 2009).
The log expression levels of individual genes were entered into a
univariate Cox proportional hazards regression model. Genes with
a Po0.05 were considered to be associated with DSS. Furthermore,
GSEA was performed on the cohort of 157 ovarian cancers to
evaluate associations between DSS and identified pathways.
Immunohistochemistry
Protein expression of selected enriched genes from identified
pathways was evaluated by immunohistochemistry using tissue
microarray sections. Tissue microarrays were constructed from
paraffin-embedded tumour tissue obtained at primary debulking
surgery, performed by the gynaecological oncologists from the
University Medical Center Groningen between May 1985 and April
2003. The tissue microarrays contain four 0.6mm core biopsies
from each of 361 patients. For this study, tissue samples obtained
at primary debulking surgery from 108 advanced-stage serous
ovarian cancer patients were analysed, for whom staining of TILs
and HLA-A and HLA-B/C has previously been performed and
published (Leffers et al, 2009a,b). In addition, staining was
performed for HLA-DP/DQ/DR (clone CR3/43, DAKO, Heverlee,
Belgium). In brief, after dewaxing and rehydration, 4mm sections
were microwaved in 10mM citrate buffer pH 6.0 for antigen
retrieval. Subsequently, sections were incubated overnight with the
primary antibody (dilution 1:100). Sections were subsequently
incubated with DAKO Envisionþ (DAKO). Antigen–antibody
reactions were visualised with 3,3-diaminobenzidine. Tissue was
counterstained with haematoxylin.
Sections were scored independently by two observers (MG/NL)
who were unaware of clinicopathological characteristics and
the TIL status of patients. A semiquantitative quality control
system was used taking into account both the intensity of staining
and the percentage of positive tumour cells as previously described
(Leffers et al, 2009b). The sum of both scores was used to identify
three categories of expression: no expression (total score 0–2),
positive expression in a proportion of cells or weak expression
in all cells (total score 3–6), and positive expression in a majority
of cells (total score 7 and 8). Only patients for whom at least two
evaluable cores were available were included for further analysis.
Associations between CD8
þ TIL and protein expression of
selected enriched genes in identified pathways were evaluated
using the Jonckheere–Terpstra test (a form of the Kruskal–Wallis
test that also tests for linearity). The Mann–Whitney U-test was
used to evaluate associations between CD8
þ TIL and well-known
prognostic factors (i.e., age, FIGO stage, histological grade, and
residual tumour after primary debulking surgery). Disease-specific
survival was defined as the date of surgery until the date of death
because of ovarian cancer (including fatal complications of
treatment) or the date of last follow-up. Differences in DSS based
on protein expression levels were plotted using Kaplan–Meier
survival curves and evaluated using log-rank tests. SPSS software
package for Windows, version 16.0 (SPSS Inc., Chicago, IL, USA)
was used. P-values of o0.05 were considered statistically
significant.
RESULTS
Patient characteristics
Microarray data of 49 advanced-stage serous ovarian cancer
patients with either low (n¼25) or high numbers of CD8
þ TILs
(n¼24) were evaluated (Figure 1). Clinical and pathological
characteristics as well as tumour percentage of the samples used
for microarray did not differ between patients with low or high
numbers of CD8
þ TILs (Table 1). Median DSS was higher for
patients with high CD8
þ TILs (log-rank test P¼0.025).
Differential expression of genes and biological pathway
analysis
A comparison of the expression levels of all 15909 genes
showed differential expression of 320 genes between tumours
containing low and high numbers of CD8
þ TILs (Po0.05). The
differences between low and high CD8
þ TIL samples were small
(Supplementary Table 1). In view of these small differences, we
subsequently evaluated whether coordinated differences in genes
belonging to a single biological pathway existed rather than
differences in the expression levels of single genes. In all, 14
pathways in BIOCARTA and 8 pathways in KEGG (Po0.05, FDR
o0.25) were enriched in tumour samples with high numbers of
CD8
þ TILs, whereas only one pathway was enriched in tumour
samples with low CD8
þ TIL numbers (Table 2). Interestingly, and
conveniently serving as an internal control, one of the pathways
enriched in high CD8
þ TIL tumours was the CTL-mediated
Study on tumour-infiltrating T lymphocytes (n =306)
Late-stage serous ovarian cancer patients with known CD8+
T lymphocyte status in primary ovarian tissue (n=108)
Gene profiling study
Late-stage serous ovarian
cancer patients (n=157)
320 differentially expressed genes
23 differentially activated pathways
Validation 1:
Association of identified genes
and pathways with DSS (n =157)
N =49
Low TIL (<5/0.283  mm
2): n =25
High TIL (>8/0.283  mm
2): n =24
Validation 2:
Immunohistochemical evaluation of enriched genes from
antigen processing and presentation pathway (n =108)
Figure 1 Flowchart illustrating patient selection and validation. Index and validation patients were selected from previous studies at our institute
investigating the prognostic effect of gene expression (Crijns et al, 2009) and tumour-infiltrating lymphocytes on ovarian cancer patients (Leffers et al, 2009a).
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simmune response pathway. We subsequently performed leading-
edge subset analysis to identify key regulatory genes common to
the enriched pathways (Table 3), which among others identified
several genes encoding for HLA molecules.
Effect on DSS
Univariate survival analysis was performed to assess the prog-
nostic value of the 320 genes identified as differentially expressed
between high and low CD8
þ TIL tumours, using 157 late-stage
serous ovarian cancer patients previously profiled at our institute
(Crijns et al, 2009). A significant association with DSS was
observed for 54 genes (Table 4). Of the 23 genes associated
with high CD8
þ TIL tumours, 21 were associated with improved
survival. Conversely, 27 of 31 genes associated with low CD8
þ TIL
tumours were associated with decreased survival (Figure 2).
We next performed GSEA to identify which pathways were asso-
ciated with DSS. Eight pathways associated with the presence of
CD8
þ TIL, such as the antigen processing and presentation path-
way, were also positively associated with DSS (Table 2).
The interdependency of these pathways has been visualised in
Figure 3A and B.
Immunohistochemical validation
On the basis of GSEA and leading-edge subset analysis, which
showed that the presence of TILs was associated with the
expression of MHC class I and II genes as part of the antigen
processing and presentation pathway, we evaluated immunohis-
tochemical staining of HLA-A, HLA-B/C, and HLA-DP/DQ/DR in
108 advanced-stage serous ovarian cancer patients for whom
information on CD8
þ TILs was available, part of which was
previously published for a larger patient cohort (Leffers et al,
2009a,b). Partial or total loss of HLA-A and HLA-B/C was
observed in 70.4 and 62.0% of patients, respectively, whereas HLA-
DP/DQ/DR upregulation was observed in 68.5% of patients.
Increasing levels of MHC class I and II protein expression
strongly correlated with increased numbers of CD8
þ TILs
(Table 5). However, no association was observed between the
expression of HLA-A, HLA-B/C, and HLA-DP/DQ/DR with DSS
(P¼0.114, P¼0.599, and P¼0.692, respectively).
DISCUSSION
Although it has been well established that TILs are predictors of
DSS in ovarian cancer, it is largely unknown what factors
contribute to the presence of these lymphocytes. By comparing
gene expression profiles of 25 tumours containing low and 24
tumours containing high numbers of CD8
þ TILs, we identified 320
genes differentially expressed by primary tumours of late-stage
serous ovarian cancer patients. In addition, for 54 of these genes,
an association with survival was observed in a large validation
cohort containing 157 advanced-stage serous ovarian cancer
Table 1 Clinicopathological characteristics and survival data of patients with known CD8
+ TIL status
Patients in microarray analyses
IHC validation set
Low TIL (n¼25) High TIL (n¼24) P-value (n¼108)
Age (years)
Mean (s.d.) 62.4 (14.5) 60.8 (12.9) NS* 60.2 (13.2)
DSS (months)
Median (95% CI) 10.8 (8.7–13.0) 19.4 (1.0–37.7) 0.025 19.9
a (8.4–31.3)
FIGO stage
Stage III 19 (76.0%) 20 (83.3%) NS 87 (80.6%)
Stage IV 6 (24.0%) 2 (16.7%) 21 (19.4%)
Tumour grade
Grade I 1 (4.0%) 2 (8.3%) NS 6 (5.6%)
Grade II 10 (40.0%) 5 (20.8%) 28 (25.9%)
Grade III/undifferentiated 13 (52.0%) 16 (66.7%) 67 (62.0%)
Missing 1 (4.0%) 1 (4.2%) 7 (6.5%)
Residual disease
o2cm 5 (20.0%) 6 (25.0%) NS 33 (30.6%)
X2cm 20 (80.0%) 16 (66.7%) 66 (61.1%)
Missing — 2 (8.3%) 9 (8.3%)
Type of chemotherapy
No chemotherapy 3 (12.0%) 1 (4.2%) NS 6 (5.6%)
Platinum containing 11 (44.0%) 12 (50.0%) 41 (38.0%)
Platinum and taxane containing 8 (32.0%) 8 (33.3%) 48 (44.4%)
Other 2 (8.0%) 3 (12.5%) 10 (9.3%)
Missing 1 (4.0%) — 3 (2.8%)
CD8
+
Median (IQR) 1.0 (0.5–2.5) 24.0 (16.0–62.5) o0.001 8.0 (2.0–22.8)
% Tumour in microarray sample
Median (IQR) 63 (50.0–80.0) 70 (52.5–78.0) NS
Abbreviations: DSS¼disease-specific survival; FIGO¼International Federation of Gynaecology and Obstetrics; CI¼confidence interval; IHC¼immunohistochemistry; NS¼not
significant; IQR¼interquartile range; TIL¼tumour-infiltrating lymphocyte.
aOnly two patients died from other causes than ovarian cancer or treatment-related fatalities.
*PX0.05.
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spatients. Genes connected to high CD8
þ TIL tumours were
associated with improved survival. With GSEA, next to pathways
merely reflecting the presence of lymphocytes, several pathways
were identified to be associated with the (lack of) CD8
þ TILs,
some of which were also associated with survival in our validation
set. Lastly, the association of a number of genes from the enriched
antigen processing and presentation pathway with the presence of
CD8
þ TIL was confirmed using immunohistochemistry.
Our study illustrates that gene expression profiling is a valuable
approach to elucidate what tumour cell characteristics contribute
to or impede recruitment of lymphocytes into serous ovarian
cancer. However, a problem inherent to the design of our study is
the impossibility to discern what genes were expressed by tumour
cells and what signal was derived from TILs themselves. This is
substantiated by the fact that some of the pathways found to be
enriched in high CD8
þ TIL tumours are lymphocyte-specific
pathways, for example, T cytotoxic pathway. To our advantage,
this observation can also be regarded to validate the immunohis-
tochemical evaluation of CD8
þ T-cell count used for patient
selection. To avoid the signal from lymphocytes, one should profile
a limited number of tumour cells, which could be accomplished by
microdissection of tumour cells (Glanzer and Eberwine, 2004).
However, as with decreasing cell numbers, RNA yield also reduces
such assays heavily depend on mRNA amplification. Especially
genes with low numbers of transcripts may be under-represented
after amplification and thus not identified in subsequent profiling
studies (Nygaard et al, 2005). For this study, we therefore decided
that, as the percentage of tumour cells did not differ between
samples with low and high numbers of CD8
þ TILs, it was safe to
assume that differences in non-lymphocyte-restricted genes and
pathways reflected differences in gene expression by tumour cells.
Ultimately, our study was intended not only to establish what
tumour factors contribute to lymphocyte recruitment, but also to
discover putative factors that might enhance clinical results of
immunotherapy for ovarian malignancies by improving lympho-
cyte recruitment when targeted. In this respect, one of the
interesting genes identified as differentially expressed between
high CD8
þ TIL and low CD8
þ TIL tumours and associated with
DSS of late-stage serous ovarian cancer patients is interferon
regulatory factor 1 (IRF-1). Recently, IRF-1 was reported to be a
positive prognostic factor in ovarian and colorectal cancer (Galon
et al, 2006; Zeimet et al, 2009) and was found to be associated with
infiltration of CD8
þ T lymphocytes in ovarian cancer (Callahan
et al, 2008). Binding of IFN-g to the IFN-g receptor leads to
upregulation of IRF-1, which in turn results in: (1) induction of
IFN-g-inducible genes, such as the TAP1, LMP2, and b2-micro-
globulin genes of the MHC class I-dependent pathway, as well as
(2) activation of CIITA, a critical transcription factor for MHC
Table 3 Results of leading-edge analysis identifying genes common to
enriched pathways
KEGG BIOCARTA
Gene symbol N gene sets Gene symbol N gene sets
HLA-A 4 CD3D 5
HLA-B 4 ITGBB2 3
HLA-DRB1 4 CD3E 4
HLA-DRB2 4 HLA-DRB1 3
IL1B 4 CFS2 3
TNFA1 4 IL5 3
HLA-DQB1 3 IL8 3
HLA-DQB2 3 CD8A 3
HLA-F 3 CYCS 3
CD8A 3 GZMB 3
NFKB1A 3 PRF1 3
RELA 3 RELA 3
IKBKB 3
PIK3R3 3
CSF2 3
IL8 3
CCL5 3
CD40 3
Abbreviation: KEGG¼Kyoto Encyclopedia of Genes and Genomes.
Table 2 Enriched pathways in tumour samples with high CD8
+ TIL identified by gene set enrichment analysis using pathway definitions from
BIOCARTA and KEGG
Pathway Database P-value FDR Enriched in
Ribosome pathway KEGG 0.0 0.0 Low CD8+ TIL
Antigen processing and presentation
a KEGG 0.0 0.0 High CD8+ TIL
Type I diabetes mellitus KEGG 0.0 0.006 High CD8+ TIL
Toll like receptor signalling pathway KEGG 0.0 0.055 High CD8+ TIL
Haematopoietic cell lineage
a KEGG 0.0 0.060 High CD8+ TIL
Cytokine cytokine receptor interaction
a KEGG 0.0 0.104 High CD8+ TIL
Cell adhesion molecules
a KEGG 0.0 0.137 High CD8+ TIL
Citrate cycle KEGG 0.013 0.156 High CD8+ TIL
Reductive carboxylate cycle KEGG 0.038 0.142 High CD8+ TIL
CTL pathway
a BIOCARTA 0.0 0.051 High CD8+ TIL
COMP pathway BIOCARTA 0.0 0.008 High CD8+ TIL
MITOCHONDRIA pathway BIOCARTA 0.0 0.120 High CD8+ TIL
D4GDI pathway BIOCARTA 0.005 0.105 High CD8+ TIL
AMI pathway BIOCARTA 0.005 0.225 High CD8+ TIL
DC pathway
a BIOCARTA 0.007 0.215 High CD8+ TIL
TALL1 pathway
a BIOCARTA 0.010 0.201 High CD8+ TIL
ATRBRCA pathway BIOCARTA 0.017 0.205 High CD8+ TIL
CSK pathway BIOCARTA 0.024 0.195 High CD8+ TIL
CASPASE pathway BIOCARTA 0.029 0.183 High CD8+ TIL
STEM pathway BIOCARTA 0.037 0.230 High CD8+ TIL
T CYTOTOXIC PATHWAY
a BIOCARTA 0.038 0.198 High CD8+ TIL
ATM pathway BIOCARTA 0.038 0.198 High CD8+ TIL
LAIR pathway BIOCARTA 0.046 0.231 High CD8+ TIL
Abbreviations: TIL¼tumour-infiltrating lymphocyte; FDR¼false discovery rate; KEGG¼Kyoto Encyclopedia of Genes and Genomes.
aAlso associated with improved survival in
157 previously profiled advanced-stage ovarian cancer patients (Crijns et al, 2009).
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sclass II gene expression. Thus, IRF-1 facilitates recognition of
tumour cells by immune cells, ultimately resulting in an IFN-g-
dependent positive feedback loop. Correspondingly, in high CD8
þ
TIL tumours we observed differential expression of several MHC
class I and II genes, all part of the selectively activated antigen
processing and presentation pathway. Immunohistochemical
evaluation confirmed the positive association of intra-tumoural
cytotoxic T cells with surface expression of MHC class I and II
molecules HLA-A, HLA-B/C, and HLA-DP/DQ/DR. Although
several MHC class II alleles were differentially expressed in high
CD8
þ TIL tumours, no association was found between HLA-DP/
DQ/DR membrane expression and survival. Moreover, only
HLA-DQB2, a virtually non-polymorphic gene, was associated
with DSS in our large validation cohort (Gaur et al, 1992). As it
Table 4 Genes differentially expressed between high and low CD8
+ TIL tumours that are associated with DSS in a large cohort of 157 advanced-stage
serous ovarian carcinomas
Gene symbol Description T
Parametric
P-value
lymphoc.
Parametric
P-value
survival HR
Fold change
high/low
CD8
+ TIL
ENDOG Endonuclease G  3.58818 0.000469 0.007736 0.657 1.057368
APOL6 Apolipoprotein L 6  3.51777 0.000588 0.016474 0.784 1.061243
LOC144817 Hypothetical protein loc144817  3.4572 0.000725 0.007082 0.751 1.054609
TNFRSF11B Tumour necrosis factor receptor superfamily, member 11b (osteoprotegerin)  3.2365 0.001533 0.029561 0.778 1.076219
CCL5 Chemokine (c-c motif) ligand 5  3.05761 0.002678 0.008189 0.78 1.06113
SMARCD3 SWI/SNF-related, matrix-associated, actin-dependent regulator
of chromatin, subfamily d, member 3
 2.89433 0.004415 0.012281 0.715 1.044497
HLA-DQB2 Major histocompatibility complex, class II, DQ b 1  2.62341 0.009683 0.025419 0.718 1.036787
P2RY2 Purinergic receptor P2Y, G-protein coupled, 2  2.58765 0.010682 0.04794 0.622 1.062139
HTATIP2 HIV-1 tat interactive protein 2, 30kda  2.50033 0.013646 0.023893 0.749 1.04496
ITGB4 Integrin, b 4  2.4564 0.015268 0.02019 0.788 1.042571
BRSK1 BR serine/threonine kinase 1  2.4344 0.016188 0.001032 0.634 1.043443
CD74 CD74 antigen (invariant polypeptide of major histocompatibility complex,
class II antigen-associated)
 2.39153 0.018114 0.048429 0.798 1.0387
IRF1 Interferon regulatory factor 1  2.38234 0.018578 0.018766 0.731 1.039269
CARD9 Caspase recruitment domain family, member 9  2.34654 0.020354 0.012632 0.733 1.053982
GBP5 Guanylate binding protein 5  2.29852 0.023022 0.026438 0.789 1.053155
OR4K1 Olfactory receptor, family 4, subfamily k, member 1  2.25082 0.025956 0.027515 0.535 1.043061
IDH3A Isocitrate dehydrogenase 3 (nad+) a  2.19777 0.029762 0.004543 0.539 1.042238
RARRES3 Retinoic acid receptor responder (tazarotene induced) 3  2.17032 0.031671 0.027127 1.26 1.039329
GUCY2F Guanylate cyclase 2f, retinal  2.09159 0.038394 0.030464 0.683 1.064628
C1orf151 Chromosome 1 open reading frame 151  2.08091 0.039363 0.000145 0.582 1.037702
PUM2 Pumilio homologue 2 (drosophila)  2.04334 0.042905 0.037206 1.617 1.026572
SUSD3 Sushi domain containing 3  2.04205 0.043025 0.0087 0.791 1.041484
GRM3 Glutamate receptor, metabotropic 3  2.02279 0.045086 0.007333 0.602 1.037417
RP9 Retinitis pigmentosa 9 (autosomal dominant) 1.979686 0.049732 0.02947 0.506 0.970948
TPM2 Tropomyosin 2 (b) 2.01335 0.046075 0.002014 1.459 0.968061
CREB3L4 cAMP responsive element binding protein 3-like 4 2.024371 0.044851 0.024523 1.448 0.969375
ADFP Adipose differentiation-related protein 2.028392 0.044437 0.004516 1.279 0.954856
ZIC1 Zic family member 1 (odd-paired homologue, drosophila) 2.034892 0.043757 0.024456 1.214 0.941812
TCF4 Transcription factor 4 2.038027 0.043448 0.041311 1.317 0.965471
RKHD1 Ring finger and KH domain containing 1 2.054802 0.041812 0.026765 0.6 0.971522
AKAP12 A kinase (PRKA) anchor protein (gravin) 12 2.05607 0.041754 0.020387 1.448 0.965955
CENPF Centromere protein f, 350/400ka (mitosin) 2.079257 0.039457 0.017257 1.28 0.955777
TF Transferrin 2.085059 0.039044 0.019715 1.302 0.95165
MARCKS Myristoylated alanine-rich protein kinase c substrate 2.085433 0.038849 0.01913 1.361 0.967259
FBN3 Fibrillin 3 2.08694 0.038733 0.008793 1.266 0.942574
TSPAN13 Tetraspanin 13 2.102597 0.037447 0.00351 1.465 0.962836
C1orf85 Chromosome 1 open reading frame 85 2.149681 0.033301 0.009093 1.684 0.969927
NT5C2 50-nucleotidase, cytosolic II 2.151955 0.033136 0.042652 0.735 0.959484
DAD1 Defender against cell death 1 2.163076 0.032559 0.039308 1.509 0.971288
COL11A1 Collagen, type xi, a 1 2.180716 0.03094 0.008437 1.149 0.926402
GLT25D1 Glycosyltransferase 25 domain containing 1 2.183846 0.030707 0.011982 1.464 0.966298
GMFB Glia maturation factor, b 2.381146 0.018725 0.011898 1.432 0.962138
SNRPE Small nuclear ribonucleoprotein polypeptide e 2.38174 0.018656 0.012262 1.462 0.983812
ZNF281 Zinc-finger protein 281 2.473985 0.014571 0.023546 1.587 0.957854
FABP4 Fatty acid binding protein 4, adipocyte 2.485825 0.014192 0.025061 1.11 0.908835
SAE2 SUMO1 activating enzyme subunit 2 2.489129 0.014051 0.018709 1.535 0.965225
BASP1 Brain abundant, membrane attached signal protein 1 2.533806 0.012459 0.032678 1.235 0.94384
ARMCX3 Armadillo repeat containing, x-linked 3 2.563703 0.011458 0.006661 1.562 0.94847
CPVL Carboxypeptidase, vitellogenic-like 2.690174 0.008038 0.048239 1.295 0.957396
FMOD Fibromodulin 2.76574 0.006462 0.012624 1.289 0.945678
C3orf59 Chromosome 3 open reading frame 59 2.822682 0.005501 0.022204 1.433 0.950026
PXDN Peroxidasin homologue (drosophila) 2.920898 0.004082 0.049685 0.746 0.94662
MEST Mesoderm specific transcript homologue (mouse) 3.590373 0.000463 0.002053 1.328 0.940516
HMGA2 High mobility group at-hook 2 3.770553 0.00024 0.031783 1.128 0.886346
Abbreviations: DSS¼disease-specific survival; TIL¼tumour-infiltrating lymphocyte; HR¼hazard ratio.
Genes and pathways involved in lymphocyte infiltration
N Leffers et al
690
British Journal of Cancer (2010) 103(5), 685–692 & 2010 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sencodes six thus far unknown putative proteins, the association of
HLA-DQB2 with CD8
þ TILs and survival is intriguing and
deserves further investigation.
Although we previously reported decreased survival for ovarian
cancer patients in association with HLA-B/C downregulation, an
association with survival was observed neither at mRNA nor
protein level in this study (Leffers et al, 2008). The difference in
prognostic effect observed in this study could be explained by
differences in study population and/or size. In this study a
homogeneous population of 108 late-stage serous ovarian cancer
patients was used for immunohistochemical validation. Renewed
analysis of the previously published data using only late-stage
serous ovarian cancer patients (n¼151) did not yield a correlation
of HLA-B/C expression with DSS either (data not shown).
To our knowledge, only one study attempting a better under-
standing of mechanisms underlying the infiltration by CTLs of
serous ovarian cancer by gene profiling of tumour samples has
previously been published (Callahan et al, 2008), although the
genetic signature of ovarian cancer containing high numbers of
regulatory T cells was recently published (Barnett et al, 2010).
It seems that here too genes of the antigen presentation pathway
have a major role. Three genes seem to be important for both
recruitment of regulatory FoxP3
þ and cytotoxic CD8
þ lympho-
cytes, that is, CCL5, APOL6, and IRF-1. In the study of Callahan
et al (2008) that profiled 38 high-grade advanced-stage ovarian
carcinomas, 81 genes were associated with CD8
þ T-cell infiltrate.
Only two of these genes, IRF-1 and CXCR6, were also found to be
differentially expressed in our cohort of 49 serous advanced-stage
ovarian cancer patients (P¼0.018578 resp. P¼0.035424). Several
possible explanations for the lack of concordance in identified
genes exist. Technique-specific issues, including choice of micro-
array platform and randomisation of samples on arrays, may
impede overlap in results (Draghici et al, 2006). Furthermore,
differences in patient population exist between the two studies, for
example, only high-grade tumours vs low and high-grade tumours
in our study. An additional difficulty, inherent to microarray
studies, is the use of small patient cohorts to evaluate large
numbers of potential predictors of lymphocyte recruitment. This
raises the likelihood of finding distinctive patterns based on
chance rather than on biology, a phenomenon called overfitting
(Fehrmann et al, 2007). Overfitting reduces the chances of finding
overlap on the level of individual genes between studies, which can
be countered by paying more attention to overlap in functional
gene sets rather than individual genes (Crijns et al, 2009).
Despite these challenges, the expression of IRF-1, described
above, and of CXCR6 was positively associated with the presence
of CD8
þ TILs in both studies. Recently, it was established that
both the chemokine receptor CXCR6 and its ligand CXCL16 are
not only expressed by immune cells, but also by carcinomas
(Meijer et al, 2008). Moreover, radiation was shown to recruit
lymphocytes to carcinomas through the release of CXCL16 by
tumour cells (Matsumura et al, 2008). Whether the expression of
CXCR6 is similarly induced by radiation and/or chemotherapy and
also influences lymphocyte attraction remains to be investigated.
Not only was there a discrepancy between identified genes
between our study and that of Callahan et al (2008), we also found
a substantial difference in genes and pathways associated with
survival between the present and our previous study (Crijns et al,
2009). An important reason for this divergence is a difference in
approach. Whereas the association with survival was the primary
focus of our previous study, the current study was designed to
discover genes and pathways that might be linked to lympho-
cyte recruitment. Only identified genes and pathways were
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Figure 2 Scatterplot illustrating clustering of differentially expressed
genes with survival. Genes with T-value o0.0 are differentially expressed in
high CD8
þ TIL tumours, and genes with T-value 40.0 are differentially
expressed in low CD8
þ TIL tumours. Hazard ratio o1.0 shows increased
survival, whereas hazard ratio 41.0 shows worse survival.
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Figure 3 Heatmaps showing interdependency of pathways associated
with disease-specific survival and CD8
þ T lymphocyte infiltration. (A)P a t h -
ways from KEGG database and (B) pathways from BIOCARTA database.
Table 5 Association of HLA protein expression evaluated by immuno-
histochemistry with CD8
+ TILs in serous advanced-stage ovarian cancer
CD8
+ T lymphocytes
N (%) M IQR ZP -value
a
HLA-A
Total loss 27 (25.0) 1.0 1.0–12.0 3.96 o0.001
Partial loss 49 (45.4) 9.0 4.0–22.0
Normal expression 32 (29.6) 14.0 4.8–55.3
HLA-B/C
Total loss 23 (21.3) 2.0 1.0–15.0 4.19 o0.001
Partial loss 44 (40.7) 6.0 2.0–19.8
Normal expression 41 (38.0) 16.0 5.5–30.5
HLA-DP/DQ/DR
No expression 34 (31.5) 2.0 1.0–11.0 3.36 0.001
Upregulation 52 (48.1) 12.0 5.0–24.0
Strong upregulation 22 (20.4) 14.5 4.5–43.0
Abbreviations: M¼median; IQR¼interquartile range; TIL¼tumour-infiltrating
lymphocyte.
aCalculated using Jonckheere–Terpstra test.
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although related, reason is the fact that for the present study we
were less stringent in the selection of genes (Po0.05), as we were
primarily interested in associations with lymphocyte recruitment
rather than survival, although for the 86-gene profile only genes
meeting a Po0.001 were selected (Crijns et al, 2009). Thus, only
two genes associated with survival in the current study were also
part of the 86-gene profile, that is, BRSK1 and C1orf151. Neither
gene has so far been further investigated to explain its prognostic
effect and/or role in lymphocyte recruitment.
In summary, this study shows that gene expression profiling and
pathway analysis are valuable strategies to obtain more insight into
what tumour characteristics contribute to lymphocyte recruitment
to advanced-stage serous ovarian carcinomas. Identified genes and
pathways need to be further validated and evaluated for their value
as a therapeutic target.
Supplementary Information accompanies the paper on British
Journal of Cancer website (http://www.nature.com/bjc)
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